{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:00:13Z","timestamp":1761663613283,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jsat.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:01:15Z","timestamp":1492646475000},"page":"37-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders"],"prefix":"10.1016","volume":"78","author":[{"given":"Andrew H.","family":"Talal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1928-2381","authenticated-orcid":false,"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Zeremski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clewert","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Kuhns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianthi","family":"Markatou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin A.","family":"Cloherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2017.04.011_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097022","article-title":"Hepatitis C viremia patterns in incident hepatitis C infection and one year later in 150 prospectively tested persons who inject drugs","volume":"9","author":"Alanko Blome","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jsat.2017.04.011_bb0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2307\/2987937","article-title":"Measurement in medicine: The analysis of method comparison studies","volume":"32","author":"Altman","year":"1983","journal-title":"The Statistician"},{"key":"10.1016\/j.jsat.2017.04.011_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2017.04.011_bb0020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M15-0320","article-title":"Limited access to new hepatitis C virus treatment under State Medicaid programs","volume":"163","author":"Canary","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2017.04.011_bb0025","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1478-3231.2011.02494.x","article-title":"Hepatitis C virus infection in USA: An estimate of true prevalence","volume":"31","author":"Chak","year":"2011","journal-title":"Liver International"},{"key":"10.1016\/j.jsat.2017.04.011_bb0030","article-title":"Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen","author":"Chevaliez","year":"2016","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.jsat.2017.04.011_bb0035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/cid\/ciu782","article-title":"Hepatitis C core antigen testing: A reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection","volume":"60","author":"Cresswell","year":"2015","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jsat.2017.04.011_bb0040","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3748\/wjg.v13.i17.2406","article-title":"Hepatitis C virus proteins","volume":"13","author":"Dubuisson","year":"2007","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0045","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2017.04.011_bb0055","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2017.04.011_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/M16-0065","article-title":"Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: A systematic review and meta-analysis","volume":"165","author":"Freiman","year":"2016","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2017.04.011_bb0065","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1302973","article-title":"Hepatitis C in the United States","volume":"368","author":"Holmberg","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2017.04.011_bb0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/rmv.717","article-title":"Hepatitis C core Ag and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow-up?","volume":"22","author":"Hosseini-Moghaddam","year":"2012","journal-title":"Reviews in Medical Virology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jcv.2011.05.003","article-title":"Hepatitis C virus core antigen: Analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay","volume":"51","author":"Medici","year":"2011","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0080","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.jsat.2017.04.011_bb0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jcv.2015.02.015","article-title":"Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users","volume":"66","author":"Mixson-Hayden","year":"2015","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0090","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2017.04.011_bb0095","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1128\/JCM.42.4.1631-1636.2004","article-title":"Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in Thai injection drug users","volume":"42","author":"Netski","year":"2004","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jsat.2017.04.011_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1423-0410.2000.7820080.x","article-title":"Detection of hepatitis C core antigen in the antibody negative \u2018window\u2019 phase of hepatitis C infection","volume":"78","author":"Peterson","year":"2000","journal-title":"Vox Sanguinis"},{"key":"10.1016\/j.jsat.2017.04.011_bb0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0115","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1128\/JCM.01640-09","article-title":"Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification","volume":"48","author":"Ross","year":"2010","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0120","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR - Recommendations and Reports"},{"year":"1990","series-title":"Robust estimation and testing","author":"Staudte","key":"10.1016\/j.jsat.2017.04.011_bb0125"},{"key":"10.1016\/j.jsat.2017.04.011_bb0130","doi-asserted-by":"crossref","first-page":"S747","DOI":"10.1016\/S0168-8278(16)01455-0","article-title":"Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus (HCV) management for individuals on opioid agonist treatment [abstract #SAT-115]","volume":"64","author":"Talal","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2893.2012.01630.x","article-title":"Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response","volume":"20","author":"Tedder","year":"2013","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.jsat.2017.04.011_bb0140","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1128\/JCM.02448-06","article-title":"Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis","volume":"45","author":"Ticehurst","year":"2007","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1016\/j.jsat.2017.04.011_bb0145","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMe1513245","article-title":"Simple, effective, but out of reach? Public health implications of HCV drugs","volume":"373","author":"Ward","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2017.04.011_bb0150","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1128\/JVI.75.23.11392-11400.2001","article-title":"Cross-reactivity between hepatitis C virus and influenza a virus determinant-specific cytotoxic T cells","volume":"75","author":"Wedemeyer","year":"2001","journal-title":"Journal of Virology"},{"author":"World Health Organization","key":"10.1016\/j.jsat.2017.04.011_bb0155"},{"key":"10.1016\/j.jsat.2017.04.011_bb0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/ADM.0000000000000041","article-title":"Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance","volume":"8","author":"Zeremski","year":"2014","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2017.04.011_bb0165","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ADM.0000000000000196","article-title":"Improvements in HCV-related knowledge among substance users on opioid agonist therapy after an educational intervention","volume":"10","author":"Zeremski","year":"2016","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2017.04.011_bb0170","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.3748\/wjg.v19.i44.7846","article-title":"Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care","volume":"19","author":"Zeremski","year":"2013","journal-title":"World Journal of Gastroenterology"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547217300442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547217300442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:46:16Z","timestamp":1760039176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547217300442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":33,"alternative-id":["S0740547217300442"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2017.04.011","relation":{},"ISSN":["0740-5472"],"issn-type":[{"type":"print","value":"0740-5472"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C virus core antigen: A potential alternative to HCV RNA testing among persons with substance use disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}